Article
The Clinical Significance of BCR-ABL1 Mutations in Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation.
Transplantation and cellular therapy - 1 Jun 2022
Tachibana Takayoshi, Kondo Takeshi, Uchida Naoyuki, Doki Noriko, Takada Satoru, Takahashi Satoshi, Yano Singo, Mori Takehiko, Kohno Akio, Kimura Takafumi, Fukuda Takahiro, Atsuta Yoshiko, Nagamura-Inoue Tokiko
Abstract excerpt
The global standard therapy for chronic myeloid leukemia (CML) is tyrosine kinase inhibitors (TKIs). One of the causes of therapeutic resistance to some TKIs corresponds to point mutations in the BCR-ABL1 fusion gene. Allogeneic hematopoietic cell transplantation (HCT) is a treatment option for high-risk CML, including TKI resistance. Although BCR-ABL1 point mutations comprise a major factor in the assessment of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.